Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec;96(12):e70099.
doi: 10.1002/jmv.70099.

Systems Immunology Approaches to Understanding Immune Responses in Acute Infection of Yellow Fever Patients

Affiliations

Systems Immunology Approaches to Understanding Immune Responses in Acute Infection of Yellow Fever Patients

André N A Gonçalves et al. J Med Virol. 2024 Dec.

Abstract

In the 2018 yellow fever (YF) outbreak in Brazil, we generated new transcriptomic data and combined it with clinical and immunological data to decode the pathogenesis of YF. Analyzing 79 patients, we found distinct gene expression patterns between acute YF, other viral infections, and the milder YF-17D vaccine infection. We identified a critical role for low-density, immature neutrophils in severe outcomes, marked by the downregulation of genes essential for neutrophil migration and maturation, such as PADI4, CSF3R, and ICAM1, in deceased patients. Our study also revealed complex interactions among inflammation-related genes, including increased CXCL10 and IL1R2 expression and decreased IL-1b expression in the acute phase. The diminished expression of HLA class II genes indicates impaired antigen presentation. These findings highlight the delicate balance of immune responses in YF pathogenesis and lay the groundwork for future therapeutic and diagnostic advancements.

Keywords: PBMC transcriptome; system biology analysis; yellow fever infection.

PubMed Disclaimer

References

    1. T. Garske, M. D. Van Kerkhove, S. Yactayo, et al., and for the Yellow Fever Expert Committee, “Yellow Fever in Africa: Estimating the Burden of Disease and Impact of Mass Vaccination From Outbreak and Serological Data,” PLoS Medicine 11, no. 5 (2014): e1001638, https://doi.org/10.1371/journal.pmed.1001638.
    1. C. I. Paules and A. S. Fauci, “Yellow Fever – Once Again on the Radar Screen in the Americas,” New England Journal of Medicine 376, no. 15 (2017): 1397–1399, https://doi.org/10.1056/NEJMp1702172.
    1. A. T. W. Song and L. A. Carneiro D'Albuquerque, “Acute Liver Failure Secondary to Yellow Fever: A Challenging Scenario,” Clinical Liver Disease 13, no. 2 (2019): 58–61, https://doi.org/10.1002/cld.784.
    1. M. A. Johansson, P. F. C. Vasconcelos, and J. E. Staples, “The Whole Iceberg: Estimating the Incidence of Yellow Fever Virus Infection From the Number of Severe Cases,” Transactions of the Royal Society of Tropical Medicine and Hygiene 108, no. 8 (2014): 482–487, https://doi.org/10.1093/trstmh/tru092.
    1. J. Fradico, A. C. Campi‐Azevedo, E. Speziali, et al., “Serum Soluble Mediators as Prognostic Biomarkers for Morbidity, Disease Outcome, and Late‐Relapsing Hepatitis in Yellow Fever Patients,” Clinical Immunology (Orlando, Fla.) 251, no. June (2023): 109321, https://doi.org/10.1016/j.clim.2023.109321.

Substances